Stuttgart, February 11, 2019 – Haselmeier is a leading solution provider for self-injection devices. As an innovative and strategic partner for pharmaceutical and biotechnology companies, Haselmeier develops and produces customized, unique self-injection systems that are used worldwide. The quality, reliability and ease of use of these high-tech products play a key role in the therapeutic efficiency and quality of life of patients.
Haselmeier has been in possession of an allowance to manufacture pharmaceuticals since December 2018, which is done at the production site in Buchen, Odenwald, in accordance with §13 of the Medicines Act (Arzneimittelgesetz – AMG) or according to Art. 40 of Directive 2001/83/EC. Haselmeier can now offer pharmaceutical and biotechnological companies an assembly, labelling and packaging service.
Konrad Betzler, Chief Quality Officer of Haselmeier: “I am pleased that, after extensive preparatory work and in close coordination with the responsible GMP supervisory authority, we have now received the manufacturing permit”.
Haselmeier will in future assemble the cartridges supplied by customers for the respective therapies with the injection pens as well as label and package the combination products. This service also includes the manufacture of batches for stability testing. Haselmeier thus offers important complete solutions, for example for pharmaceutical companies in the production of small and medium-sized series for clinical studies as well as for biotech start-ups.
Haselmeier, headquartered in Stuttgart, is a leading provider of subcutaneous injection system solutions. As a reliable development partner, Haselmeier provides customized solutions from concept design and prototyping to engineering and industrialization, including pharmaceutical packaging solutions. The company currently employs 240 staff members in six countries with distribution offices in Europe, the US and India, and state-of-the-art manufacturing plants in Buchen, Odenwald (Germany), Dnešice (Czech Republic) and Bengaluru (India). In 2020, the company can look back on a 100 year success story. For further information, please refer also www.connected.haselmeier.com
CAMBRIDGE, United States, May 2, 2018 – Haselmeier, a Swiss-based developer and manufacturer of innovative self-injection devices, and Common Sensing, a Cambridge-based smart injector monitoring and support solutions company, today announced a partnership agreement to develop smart connected monitoring and support solutions for users of injectable medicines.
Continue reading “Haselmeier and Common Sensing Enter Connected Injectable Medicine Collaboration”
Haselmeier has a worldwide reputation for its patient-friendly, high-tech innovations. The new
Pergoveris® Pen, developed for its customer Merck, has once again confirmed the company’s
high standard of development.
The well-respected and listened to member of the medical device community, Paul Jansen, started in his new position as senior advisor on February 1, 2017. This appointment is a perfect fit to serve the objectives of Haselmeier AG as the innovation organization within the Haselmeier Group.
Haselmeier has not even officially presented its latest innovation and the D-Flex. Just one. has already won an award: The especially flexible disposable pen D-Flex has been given the GOOD DESIGN™ Award. However, the D-Flex stands out in the market primarily thanks to its uniqueness. No comparable product can be deployed so flexibly and at the same time deliver patient safety.
Haselmeier is pleased to announce that its newest production facility in Bengaluru (India) received its official certification from TÜV SÜD on 21st September 2016. Haselmeier is now in a position to supply the Asian market more easily and more effectively with medication dosage systems and, as a result, significantly improve life for patients.
There’s a lot happening at Haselmeier! As the next step in the consistent reorganisation process of the Haselmeier Group, some activities are being moved to other locations to guarantee greater focus on strategic and operative tasks.
Zurich, Switzerland, June 06, 2016 – Berlin-Chemie launched the new BerliPen® areo 3 on the German market in April 2016.
Continue reading “Haselmeier announces the German launch of the BerliPen® areo 3 through Berlin-Chemie”
Haselmeier announces the launch by Merck of their GONAL-f® 2.0 prefilled pen following approval by EMA, the European Medicines Agency.
The Haselmeier Group has decided to reinforce and reorganise its Executive Board.
Continue reading “Haselmeier Group Announces the Extension and Reorganization of its Executive Board”